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Background: The recent expansion of whole-genome sequence data available from diverse animal lineages
provides an opportunity to investigate the evolutionary origins of specific classes of human disease genes. Previous
studies have observed that human disease genes are of particularly ancient origin. While this suggests that many
animal species have the potential to serve as feasible models for research on genes responsible for human disease,
it is unclear whether this pattern has meaningful implications and whether it prevails for every class of human
disease.
Results: We used a comparative genomics approach encompassing a broad phylogenetic range of animals with
sequenced genomes to determine the evolutionary patterns exhibited by human genes associated with different
classes of disease. Our results support previous claims that most human disease genes are of ancient origin but,
more importantly, we also demonstrate that several specific disease classes have a significantly large proportion of
genes that emerged relatively recently within the metazoans and/or vertebrates. An independent assessment of the
synonymous to non-synonymous substitution rates of human disease genes found in mammals reveals that disease
classes that arose more recently also display unexpected rates of purifying selection between their mammalian and
human counterparts.
Conclusions: Our results reveal the heterogeneity underlying the evolutionary origins of (and selective pressures
on) different classes of human disease genes. For example, some disease gene classes appear to be of uncommonly
recent (i.e., vertebrate-specific) origin and, as a whole, have been evolving at a faster rate within mammals than the
majority of disease classes having more ancient origins. The novel patterns that we have identified may provide new
insight into cases where studies using traditional animal models were unable to produce results that translated to
humans. Conversely, we note that the larger set of disease classes do have ancient origins, suggesting that many
non-traditional animal models have the potential to be useful for studying many human disease genes. Taken together,
these findings emphasize why model organism selection should be done on a disease-by-disease basis, with
evolutionary profiles in mind.
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The set of human genes implicated in Mendelian dis-
eases are of particular interest in biomedical research.
These “disease genes” contain mutations that increase
susceptibility to a disease phenotype, but are tolerated
well enough as to not cause lethality in early develop-
mental stages. Studies have demonstrated that disease
genes are a non-random subset of all human genes [1-6].
For example, human disease genes tend to be non-
essential, having relatively few interacting partners; as a
result, disease genes are often located on the periphery
of gene networks [1,2]. From an evolutionary perspec-
tive, human disease genes tend to have particularly
ancient origins [3-6], suggesting that disease-causing
mutations are more often identified in “older” genes.
Human disease genes also display unique patterns of puri-
fying selection, duplication history, and tissue-specific ex-
pression [1,4,6].
The implications of these observations in the context
of how human disease research is conducted are not
well understood. One proposition is that the tendency
for disease genes to be of ancient origins implies that
they are often functionally conserved across many ani-
mal lineages. Consequently, it may be possible to study
disease genes in a broad spectrum of animal models. For
example, a previous study estimated that over 90% of
disease genes emerged prior to the divergence of bilat-
erally symmetrical (bilaterian) animals [3]. This evolu-
tionary divergence, which dates back over 600 million
years [7], is marked by rapid innovation that gave rise to
the vast majority of animal species living today. Another
study noted that ~44% of a curated subset of disease
genes were found to have orthologs in the yeast Saccha-
romyces cerevisiae [8,9].
The use of traditional model organisms that are rela-
tively closely related to humans (including primates,
mice, and, more recently, zebrafish) has been quite suc-
cessful in yielding results that can translate to humans
[10-15], but more distantly related animals have also
been utilized for studying various human disease genes
and diseases. Pharmaceutical companies have success-
fully used Caenorhabditis elegans [16] and Drosophila
melanogaster [17] in drug discovery research. The sea
anemone Nematostella vectensis is becoming recognized
as a strikingly useful model organism, despite being a
non-bilaterian animal even more remotely related to
humans than worms and flies [9,18,19]. Most recently,
major expansions to the inventory of whole-genome se-
quences from species across the animal tree have fueled
the effort to identify and develop new model systems,
with some of these species beginning to demonstrate
real potential for the study of human disease [18,20-22].
In part, efforts to introduce new model systems to the
standard experimental repertoire are motivated by thefact that some traditional animal models more closely
related to humans present significant obstacles to re-
searchers, including high cost, slow generation time, and
complexity in measuring phenotypes. Increasingly, eth-
ical issues are also preventing the use of our closest
mammalian relatives as model organisms. In June 2013,
the National Institutes of Health announced the retire-
ment of chimpanzees in their research facilities following
a report from the Institute of Medicine demonstrating
that advances in biomedical research have enabled the
use of alternative model organisms in studies tradition-
ally utilizing chimpanzees [23]. These advances are a tes-
tament to the advent of new technologies that allow for
the direct manipulation of a model organism’s genetics
[24-26]; they also demonstrate the power of comparative
genomic techniques in improving our understanding of
animal genetics as a whole. Although there are logistical
advantages to using simpler invertebrate animals as
models, many questions remain regarding their suitabil-
ity for human disease research. The choice of model or-
ganism for any given study has many contributing
factors; primarily, a model organism must have analo-
gous biological properties to the particular human con-
dition of interest and must also be experimentally
tractable. The extensive number of animal species with
completed genome sequences provides a natural plat-
form for a fresh analysis of the evolutionary distribution
of disease genes for this purpose.
Previous studies on the origins of human disease genes
found that the early animal lineages correspond to pe-
riods of rapid innovation for human disease genes
[1-4,6], but these studies were conducted prior to the
availability of whole-genome sequence in many of these
lineages. Recent efforts to sequence the genomes of
species representing the earliest-evolving animal phyla
such as ctenophores (Mnemiopsis leidyi [27]), sponges
(Amphimedon queenslandica [28]), placozoans (Tricho-
plax adhaerens [29]), and cnidarians (Nematostella vec-
tensis [30]), as well as their closest non-animal relatives
(e.g., the unicellular filasterian Capsaspora owczarzaki
and the unicellular choanoflagellates Monosiga brevicollis
and Salpingoeca rosetta) [31], have increased our under-
standing of what shaped the evolution of multicellularity
in animals and, by extension, what biological and physio-
logical processes are universal to animals. Given these new
data, we are now able to more thoroughly investigate the
distribution of human disease genes across the Metazoa.
The utility of distantly related animal models for hu-
man disease research depends on the disease of interest
and whether or not it is feasible to study in a particular
organism. However, this distinction is not easy to make,
as it requires determining the point in evolutionary time
when a process related to human disease became func-
tionally conserved. Often, this determination is made
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under the assumptions of the “orthology-function con-
jecture” [32], would imply that sequence similarity
across species is synonymous with functional similarity.
However, there are caveats to the orthology-function
conjecture; while it tends to hold true as a generalized,
genome-scale approach for assigning function to newly
sequenced genes, contradictory cases certainly arise [32].
Furthermore, determining whether a human Mendelian
disease phenotype can be replicated in a distant ortholog
may require consideration of characteristics beyond
functional similarity, such as mutational effects and
species-specific adaptation. Thus, while orthology is use-
ful for identifying candidate genes of interest in a model
organism, other context-specific conditions still need to
be considered. Nevertheless, while the point in evolu-
tionary time in which a disease gene emerged may not
be equivalent to when it acquired its disease-related
function, these two time points are likely correlated.
Given this, the relative age of a disease gene class can be
used as a criterion in selecting an appropriate species in
which to study relevant underlying processes.
No study to date has analyzed the evolutionary distri-
butions of specific classes of human disease genes. Ra-
ther, existing studies have focused on conservation at
the levels of single genes, cancer-related genes [33], or
on the superset of all human disease genes [3,6,34].
However, different disease classes exhibit diverse proper-
ties in gene interaction networks [2]; this suggests that,
collectively, disease gene classes are not homogeneous.
We hypothesized that disease gene classes also have het-
erogeneous evolutionary origins and pressures. A num-
ber of recent high-profile cases support this perceived
heterogeneity; incongruities have been encountered be-
tween humans and closely related traditional animal
models at both the genotypic and phenotypic levels for
specific disease genes and classes, resulting in research
findings that could not be translated into new treat-
ments for human disease [14,24-26,35-40].
In this work, we have leveraged the vast amount of
new whole-genome sequence data from a broad phylo-
genetic range of animals to analyze the evolutionary dis-
tributions of specific classes of human disease genes. We
set out to accomplish three main goals: (1) to increase
the resolution of evolutionary emergence patterns of hu-
man disease genes in animals, (2) to determine whether
any specific disease classes show unique patterns of evo-
lution, and (3) to perform an initial investigation into
whether evolutionary metrics can help inform the
process of selecting appropriate animal models (includ-
ing “non-traditional” species) for studying the underlying
genetics of specific human disease classes, citing a hand-
ful of recently reported cases where results generated in
animal models could not be translated into humans.Results
Evolutionary distribution of all human disease genes
The OMIM database [41] contains a manually curated
set of human genes that are implicated in the causation
of human genetic or genomic disorders. OMIM flags the
highest confidence gene-disease associations as a “type
3” phenotype. These represent particular disease pheno-
types in which the underlying molecular basis is known
and has been mapped to a specific gene; at the time of
this writing, this encompasses 3096 human genes. To
analyze the distribution of these disease genes across an-
imals and their closest relatives (unicellular filasterians
and choanoflagellates), we overlaid the disease genes
onto clusters of orthologous genes that were generated
using a phylogenetically aware ortholog clustering algo-
rithm with predicted protein sequences from 23 species
(including human) whose genomes have been sequenced
(see Methods and Additional file 1). 2727 of the OMIM
disease genes were present in our clusters after filtering
out genes that did not map to ENSEMBL proteins (270)
or did not successfully cluster (99). Thus, using the clus-
ters that contain at least one human OMIM disease
gene, we obtain an evolutionary distribution of that dis-
ease gene based on the presence or absence of an ortho-
log in each of the 23 species.
We then analyzed the patterns in which these disease
genes emerged within the Metazoa using phylostratifica-
tion, a process by which genes are placed into major
taxonomic groups (“phylostrata”) according to their in-
ferred evolutionary emergence point [42]. We used the
presence/absence distributions within clusters to bin dis-
ease genes into phylostrata based upon the lineage in
which they first appeared in our analysis. Henceforth, we
refer to each phylostratum by the most basal classifica-
tion that it includes, although phylostrata are, in fact,
hierarchical. Our analysis considers only species as dis-
tant as the Filozoa (i.e., animals and their closest unicel-
lular relatives), so this placement does not necessarily
identify the emergence of a “founder gene” but, rather,
characterizes the evolutionary patterns of gene families
within and around animals. Figure 1 shows the full dis-
tribution of orthologs to the 2727 OMIM genes and the
corresponding phylostratification, representing the evo-
lutionary signature of all human disease genes.
In comparison to the superset of all human genes, we
identify some of the same trends noted in previous stud-
ies [3,8,9]. Specifically, we observe that more than half of
human disease genes are of ancient, pre-animal origins
(52%), a number significantly larger than would be ex-
pected if disease genes were merely a random subset of
all human genes (42.7%, p = 1.2 × 10−25 per one-tailed
hypergeometric test; see Additional files 2 and 3). We
also observe that surprisingly few human disease genes
have origins within the vertebrates or later (14.7%), as
Figure 1 Distribution of human disease gene orthologs. Heat maps showing the presence (green) or absence (red) of an ortholog for a
given human disease gene from OMIM (rows) within each species (columns). All 2727 human disease genes from OMIM are displayed. Major
phylogenetic divergence events define the six phylostratigraphic bins indicated in the phylogenetic species tree. Rows are ordered such that
disease genes first appearing in each phylostratigraphic bin (indicated by black lines) are clustered, with the corresponding percentage of the
total for each cluster projected on the stacked bar on the left. Hs, Homo sapiens; Gg, Gallus gallus; Xt, Xenopus tropicalis; Dr, Danio rerio; Ci, Ciona
intestinalis; Bf, Branchiostoma floridae; Sp, Strongylocentrotus purpuratus; Lg, Lottia gigantea; Ct, Capitella teleta; Hr, Helobdella robusta; Sm,
Schistosoma mansoni; Pp, Pristionchus pacificus; Ce, C. elegans; Dm, D. melanogaster; Dp, Daphnia pulex; Is, Ixodes scapularis; Hm, Hydra magnipapillata;
Nv, N. vectensis; Ta, T. adhaerens; Aq, A. queenslandica; Ml, M. leidyi; Mb, M. brevicollis; Co, C. owczarzaki.
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per one-tailed hypergeometric test). Notably, our inclu-
sion of newly available whole-genome sequence data
from the earliest animal lineages suggests that many hu-
man disease genes emerged with the first animals
(16.2%). As with the pre-Metazoan set, this early animal
gene set also represents a significantly larger proportion
than would be expected based on all human genes
(13.9%, p = 1.4 × 10−4 per one-tailed hypergeometric
test). Overall, the complete phylostratigraphic distribu-
tion of human disease genes versus all human genesshows a significantly ancient skew (p = 2.2 × 10−16 per χ2
two-sample test; see Additional files 2 and 3).
Species-specific human disease gene ortholog content
Given the ancient origins of the majority of the human
disease gene set, we surveyed the total human disease
gene ortholog content in the genomes of each species
included in our analysis to assess their relative similarity
to humans and, conversely, their propensity for gene loss
and lineage-specific divergence. Even the animal phyla
most distantly related to humans – ctenophores and
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contain orthologs to about half of all human disease
genes (51.6% and 56.3%, respectively; see Figure 1 and
Additional files 4 and 5). Immediately outside of the
Metazoa, these percentages drop to 39.4% (for the choa-
noflagellate Monosiga) and 41.8% (for the filasterian
Capsaspora). Our analysis identified a strikingly high
number of human disease gene orthologs in the non-
bilaterian cnidarian Nematostella (67.8%), consistent with
previously reported findings that its genome is quite
complex [9,19,30]. Comparatively, the average number of
human disease gene orthologs present in the vertebrate
(D. rerio, X. tropicalis, and G. gallus) and invertebrate (S.
purpuratus, B. floridae, and C. intestinalis) deutero-
stomes that we studied was 93% and 73%, respectively.
We do not observe a steady increase in the number of
orthologs identified relative to evolutionary divergence
times from the human lineage, suggesting lineage-specific
loss and divergence rates are not strictly dependent on
evolutionary relation to humans. The nematode C. elegans
contains orthologs to only 57.4% of human disease genes,
a proportion smaller than Nematostella and hardly larger
than the earliest branching metazoans, despite having di-
verged over 100 million years afterwards. This trend is also
observed to a lesser degree in a few other protostomes, in-
cluding the fruit fly Drosophila, whose percentage of ob-
served disease gene orthologs is 64.2%. It is well known
that the popular protostome models C. elegans and D.
melanogaster have lost a number of genes important to
human biology [9,30,43,44]. However, it is not immedi-
ately obvious whether most of these losses are shared
amongst other protostomes, or whether they tend to be
conserved in earlier-evolving phyla. Using our cluster ana-
lysis, we investigated how this particular set of disease
genes is distributed with respect to the genomes of other
animal species.
Figure 2 shows a heat map of OMIM genes in which
an ortholog is absent from both C. elegans and D. mela-
nogaster (863 out of 2727, or 31.6%). From these 863
missing genes, 292 are present in more distant non-
bilaterian lineages, of which 223 are present in at least
two such non-bilaterian species. This illustrates that
nearly one-third of all human disease genes are absent
(or highly derived) in both of these popular model or-
ganisms; in turn, one-third of these potentially represent
gene losses and are not just the result of more recent
evolutionary innovation. This analysis suggests that
roughly 10% of all human disease genes could potentially
be better-studied in selected non-bilaterian species than
in either C. elegans or D. melanogaster, with Nematos-
tella being an obvious candidate. For example, the breast
cancer susceptibility gene BRCA2 and the BRCA1-inter-
acting protein BRIP1 are identified in every species stud-
ied except for the three protostomes D. melanogaster, C.elegans, and P. pacificus, with BRCA2 additionally being
absent in L. gigantea; BRCA2 was previously identified
to be well conserved in Nematostella [9]. While these re-
mote animal species are less complex than humans, it is
quite possible that studying the most distant forms of
these genes would reveal insights into the most basic
functions they evolved to perform and, by extension,
their relationship to human disease. Additional statistics
on all species studied are available in Additional files 4
and 5.
Identification of disease classes with unique origins
On the one hand, our analysis has provided additional
evidence that the majority of the human disease gene set
has particularly ancient origins. We have expanded upon
the notion that many of our most remote animal rela-
tives contain large proportions of human disease gene
orthologs. On the other hand, it is unlikely that all dis-
ease classes follow this same evolutionary model. We
aimed to identify disease classes and disease-related bio-
logical processes that do not conform to the evolution-
ary profile exhibited by the superset of all disease genes.
Currently, there is no “gold standard” disease gene anno-
tation process that provides appreciable statistical power
for analyzing these kinds of evolutionary profiles. While
the OMIM database [41] does provide disease annotations
for individual genes, we did not utilize these annotations
because they are not guaranteed to be consistent across
the database and are not widely standardized. Instead, we
annotated the OMIM disease gene set with “level-1” and
“level-2” functional classifications generated through the
use of the Ingenuity Pathway Analysis (IPA) software suite
(Ingenuity Systems®, http://ingenuity.com). IPA classifica-
tions are based on a curated, literature-derived knowledge
base and have multiple levels of specificity; we chose to
use the top two classification levels, corresponding to
functional categories (level-1) and subcategories (level-2).
In order to select for IPA classifications related to disease
processes, we selected only those classifications whose oc-
currences were enriched in the disease gene set (Fisher’s
exact test; p < 0.05, Benjamini-Hochberg-corrected). This
method does not require that every assigned annotation
reflect the same disease-causing mutation as reported in
OMIM. Rather, a set of high-confidence annotations for
diseases and disease-related processes is produced, for
which a substantial set of known human disease genes
play a role.
For each enriched classification (and the corresponding
subset of disease genes), we replicated our cluster-based
phylostratigraphic analysis to compare the evolutionary
distribution of the annotated genes to the distribution pro-
duced using all human disease genes from OMIM (see
Figure 1). Disease-related subsets (referred to as “disease
classes” throughout) displaying a statistically significant
Figure 2 Lineage-specific loss/divergence of human disease genes in C. elegans and D. melanogaster. The subset of human disease genes
(863 of 2727; see Figure 1) absent in both D. melanogaster and C. elegans (indicated by the solid black box), one-third of which are possible gene
losses (292) due to their presence in a more distant phylostratum (dashed black box).
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(Fisher’s exact test, 2 × 6 contingency table; p < 0.05,
Bonferroni-corrected) were identified and analyzed. Of the
77 level-1 annotations considered, 48 (representing 62% of
tested disease classes) were not found to significantly devi-
ate from the null model (i.e., the pattern observed for all
OMIM genes as a whole). This included annotations for
cancer, neurological diseases, and metabolic diseases (see
Additional file 6). The results suggest that the majority of
human diseases have very ancient origins, consistent with
what we observed for the superset of all disease genes.
However, the other 29 annotations (representing 38% of
tested disease classes) were all under-represented in the
Filozoa phylostratum (Figure 3), appearing more recentlywithin the Metazoa than would be expected based on the
null distribution. The same pattern is observed when con-
sidering level-2 annotations, in which 113 out of 500 clas-
sifications (22.6%) were found to significantly deviate from
the null model, all exhibiting an under-representation in
the Filozoa (see Additional files 6, 7, 8 and 9). Thus, there
do not appear to be any disease classes with a signifi-
cantly more ancient origin than the null distribution (i.e.,
with over-representation of pre-metazoan genes), but
there is a substantial set of disease classes that are char-
acterized by sets of genes from more recent metazoan-
specific innovations.
To ensure that these results were not an artifact of the
IPA annotation process, which could potentially be
Figure 3 Disease classifications with non-conforming evolutionary origins. The 29 “level-1” disease-related annotations corresponding to
genes with significantly deviating evolutionary distribution from the null model (“All OMIM”, see Figure 1 and Methods). Individual phylostratigraphic
bins having over- or under-representation compared to the null model (Fisher’s exact test, 2 × 2 contingency table; p < 0.05) are indicated. Disease
classes are hierarchically clustered by Euclidean distance-based similarity. RespSys (Respiratory System Development and Function), AudVeSys (Auditory
and Vestibular System Development and Function), InfectDis (Infectious Disease), ImCelTra (Immune Cell Trafficking), InflamDis (Inflammatory Disease),
CellSign (Cell Signaling), Hematop (Hematopoiesis), ImmuDis (Immunological Disease), C2CSign (Cell-to-Cell Signaling and Interaction), EndocSys
(Endocrine System Disorders), VitMinMet (Vitamin and Mineral Metabolism), HemaSys (Hematological System Development and Function), InflamRes
(Inflammatory Response), HepaSys (Hepatic System Disease), LymphTis (Lymphoid Tissue Structure and Development), HemaDis (Hematological
Disease), CardioDis (Cardiovascular Disease), CellMove (Cellular Movement), ConnTis (Connective Tissue Disorders), NervSys (Nervous System Development
and Function), SkeMuSys (Skeletal and Muscular System Development and Function), GeneExp (Gene Expression), CellDev (Cellular Development),
TisMorph (Tissue Morphology), TisDev (Tissue Development), OrgDev (Organismal Development), OrganMor (Organ Morphology), OrganDev (Organ
Development), EmbryDev (Embryonic Development). A dagger (†) denotes annotations not identified as significant with an alternative phylostratification
method based on reciprocal BLASTP (see Methods).
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pared the distributions of the set of disease genes that
received no annotation (788) as well as the set that re-
ceived at least one annotation (1939) to the null model
of all OMIM genes. Both of these sets produce an evolu-
tionary distribution almost identical to the superset of
all OMIM genes (Fisher’s exact test, 2 × 6 contingency
table; p = 0.93 and p = 0.99, respectively; see Additional
file 2), suggesting that the IPA annotation process does
not produce an evolutionary bias. Therefore, we can
conclude that the 29 more recently emerging disease
classes we have identified are exceptions to the ancient
trend exhibited by the superset of all diseases, substanti-
ating our concern that many diseases do not adhere to
this overly generalized model of conservation.
Novel signatures of disease class evolutionary origins
Further analysis of the disease class-specific gene subsets
revealed four recurring evolutionary patterns. The fourpatterns include the expected distribution displayed by
all human disease genes and the majority of disease clas-
ses, with three of them being novel patterns that we
refer to as “evolutionary signatures.” The first novel sig-
nature has genes evolving at expected rates between the
emergence of metazoans and the deuterostomes, but
appearing much more frequently than expected in the
vertebrates and much less frequently prior to metazoans
(Figure 4A). We term these the “vertebrate-specific” dis-
ease classes, which are the most recently evolved, and
includes nine classifications such as Inflammatory Dis-
ease (InflamDis), Inflammatory Response (InflamRes)
and Infectious Disease (InfectDis). For example, various
sets of cytokines and their receptors were binned in the
vertebrate lineage and linked to inflammatory diseases,
including chemokines (CCLs), interleukins (ILs and
ILRs), interferons (IFNGs and IFNGRs), and immuno-
globulins (FCGRs). This group also includes some more
ancient genes, such as sodium channel transporters
Figure 4 Distinct evolutionary signatures of disease classes. Comparison of the 29 “level-1” disease-related annotations identified as having a
statistically significant evolutionary distribution (see Figure 3 and Methods), displayed relative to the distribution of the null model (all OMIM
genes). Annotations are separated into signatures for A) vertebrate-specific, B) early metazoan, and C) multi-stage metazoan disease classifications.
Only statistically significant over/under-representations of points within individual phylostratigraphic bins are plotted as non-zero (Fisher’s exact
test, 2 × 2 contingency table; p < 0.05), corresponding to those denoted in Figure 3. Points marked with an asterisk (*) denote over/under-
representations where p < 6.5 × 10−4 (p < 0.05, Bonferroni corrected for bin-specific comparisons).
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ancient genes co-opted into the inflammatory response
pathways at some point within vertebrate evolution.
The second novel signature (Figure 4B) is characterized
by a set of disease classes that are under-represented out-
side of animals and over-represented in the early animal
phyla (but not in the deuterostomes or vertebrates); we
called these the “early metazoan” disease classes. This
group of ten contains many developmental processes in-
herent to animals, including Embryonic Development
(EmbryDev), Organ Development (OrganDev), and Organ
Morphology (OrganMor), as well as processes related to
the development and function of the Nervous System
(NervSys), Skeletal and Muscular System (SkeMuSys), Re-
spiratory System (RespSys), and the Auditory and Vestibu-
lar System (AudVeSys). While some of these systems may
not have evolved in their entirety during the earliest stages
of animal evolution, the data indicate that necessary com-
ponents of these systems evolved within the Metazoa ra-
ther than prior to it, and more likely arose well before the
evolution of the vertebrates.
The third signature (Figure 4C) seemingly represents an
overlap between the “vertebrate-specific” and “early meta-
zoan” signatures; we call these the “multi-stage metazoan”
disease classes. This group of ten classes is distinguished
by an under-representation outside the Metazoa and over-
representations of lesser magnitude in both the non-
bilaterian and vertebrate lineages. A number of these
classifications include disease processes related to blood
and the cardiovascular system, namely Cardiovascular Dis-
ease (CardioDis), Hematopoiesis (Hematop), Hematological
Disease (HemaDis) and Hepatic System Disease (HepaSys).
These signatures appear to have multi-modal distribu-
tions, indicating a more complex evolutionary history
where different components of biological processes and
diseases emerged at different periods in animal evolution,
coinciding with major genomic innovation events.
Differing rates of purifying selection act on disease
classes of different age
Our phylostratigraphic analysis of disease gene age sug-
gests that most disease genes evolved before or within
the earliest vertebrate lineages. We estimate that >96%
of the disease genes emerged before the divergence of
zebrafish (D. rerio; see Figure 1). This is of particular im-
portance given that there has been rapid and remarkable
success in developing zebrafish into a standard animal
model, especially after the sequencing of its genome
[45]. However, recent cases of studies involving trad-
itional model organisms that failed to produce results
that can translate to humans [14,25,26,35-40] suggest
that consideration of disease gene age alone (or the iden-
tification of an ortholog) may not be sufficient to ration-
alize the use of an organism as an appropriate model forstudying human disease. Specifically, these reports have
found inconsistencies relative to the human phenotype
when studying inflammatory diseases in mice [35], cer-
tain immune responses in non-primates [14], and acute
myocardial infarction drug candidates in dogs and rab-
bits [37]. Our analysis identified both Inflammatory Dis-
ease (InflamDis) and Immunological Disease (ImmuDis)
as being grouped within the vertebrate-specific evolu-
tionary signature, and various disorders related to blood
and the cardiovascular system matching the multi-stage
metazoan evolutionary signature [e.g., Cardiovascular
Disease (CardioDis)]. As these two signatures are char-
acterized by the over-representation of vertebrate-
specific genes and under-representation of pre-metazoan
genes, we can infer that these are the most recently
evolved disease class signatures. Based on this inference,
we hypothesize that a correlation exists between the rela-
tive genetic age of a disease and the evolutionary distance
at which a particular model organism would be useful.
We posited that the presence of an unusual degree of
purifying selection between a class of human disease
genes and their orthologs in a model species may indi-
cate potential problems for studying that particular dis-
ease class in that model organism. It has been shown
previously that, in general, older genes evolve more
slowly than younger ones [46]. However, it has also been
shown that disease genes do not follow this trend; both
younger and older disease genes appear to evolve slowly,
at rates more similar to that of older genes [4]. Thus, we
tested how different classes of disease genes behave by
independently analyzing the selective pressures occur-
ring on genes from each of the disease classes. We fo-
cused specifically on mammalian and primate species to
see if a relationship exists between our identified signa-
tures based on disease gene age and their evolutionary
conservation within mammals. Sequence data were col-
lected from nine well-characterized species: Canis lupus
familiaris (dog), Felis catus (cat), Rattus norvegicus (rat),
Mus musculus (mouse), Oryctolagus cuniculus (rabbit),
Otolemur garnetti (bushbaby), Callithrix jacchus (mar-
moset), Macaca mulatta (macaque), and Pan troglodytes
(chimpanzee).
For each disease class, we analyzed the distribution of
dN, dS, and dN/dS values for each disease gene within
each of these mammalian species (see Methods). This
analysis was restricted to mammals in order to maintain
reliable dS rate estimates that can become saturated
over larger evolutionary distances. We then compared
these values to those calculated for the distribution of
all 2727 human disease genes described above (Mann-
Whitney U two-tailed test; p < 0.05, Bonferroni-corrected;
see Additional file 10). This process enabled us to identify,
for each mammalian model organism, disease classes hav-
ing evolutionary rates that deviate significantly from the
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visualize and quantify positive or negative deviations, me-
dian values (with 95% confidence intervals) of the distribu-
tions for each metric were computed for each class of
disease genes. Overall, the dS rates tended to follow the
distribution observed for all human disease genes, but
there were multiple cases of statistically significant devia-
tions in dN rates. Henceforth, we only refer to the dN/dS
ratio as it summarizes both statistics, noting that changes
in dN/dS are predominately driven by changes in dN rates.
Figure 5 shows the median dN/dS metric for each disease
gene class found to significantly deviate from the distribu-
tion observed for all human disease genes in each mam-
malian species. The disease classes themselves have been
grouped based on their age-based evolutionary signature
identified via phylostratigraphic analysis (i.e., vertebrate-
specific, early metazoan, or multi-stage metazoan; see
Figure 4).
Generally, the vertebrate-specific disease classes
(Figures 4A and 5A) show weaker purifying selection
than expected (i.e., median dN/dS closer to 1 as compared
to all human disease genes) in the mammalian species
considered, whereas the early-metazoan disease classes
(Figures 4B and 5B) show stronger purifying selection than
expected (i.e., median dN/dS closer to 0 as compared to
all human disease genes). The magnitude of these trends
varies for disease classes within each of the previously de-
scribed evolutionary signatures. For example, the infec-
tious disease class exhibits the largest over-representation
of vertebrate-specific genes (Figure 4A); it also demon-
strates the weakest degree of purifying selection in all
mammalian species considered (Figure 5A). On the other
end of the spectrum, vertebrate-specific disease classes
that do not exhibit as large of an over-representation of
vertebrate-specific genes (such as the connective tissue
disorders and cellular movement classes) do not signifi-
cantly deviate from the superset of all human disease
genes by the dN/dS metric. In most cases, the deviations
showing significantly weak purifying selection (i.e., dN/dS
closer to 1) more often occur in mammals of more distant
relation to humans, supporting the logical conclusion that
some disease classes are well conserved only in our closest
animal relatives, but not necessarily in all mammals. We
note that the human inflammatory disease genes tend to
show weak purifying selection rates in mammals, with the
deviation being statistically significant only in rat and
mouse; this is consistent with our hypothesis that degree
of purifying selection is related to appropriate model or-
ganism choices [35].
The multi-stage metazoan disease gene classes (Figures 4C
and 5C) again appear to represent a combination of the
vertebrate-specific and early-metazoan classes; some
show slightly weaker purifying selection and some show
slightly stronger purifying selection relative to all humandisease genes, but the magnitudes of these differences are
not considered statistically significant. The set of disease
classes that were considered non-deviating from all hu-
man disease genes via phylostratification generally were
also non-deviating in dN/dS values, with a handful (8 out
of 48) being under stronger purifying selection than all
human disease genes and having patterns similar to the
early-metazoan cases (e.g., “Behavior”, “Developmental
Disorder”, “Neurological Disease”, and “Visual System
Development and Function”; see Additional file 10).
To determine which genes are driving the deviation
patterns exhibited in Figure 5A and B, we compared the
dN/dS ratio distributions for all human disease genes be-
tween phylostrata. Only the vertebrate-specific set of hu-
man disease genes demonstrates a unique rate of purifying
selection (significantly weaker than “older” genes), whereas
all disease genes with pre-vertebrate origins are essentially
indistinguishable from each other by this metric (see
Methods and Additional file 11). This explains why disease
classes with high proportions of vertebrate-specific genes
are, overall, under weaker rates of purifying selection. It is
important to note that we cannot rule out the possibility
that difficulties in identifying distant homologs of rapidly
evolving genes could lead us to believe that they are youn-
ger. However, the stronger rates of purifying selection ob-
served in the early-metazoan disease classes seem to be
more context-specific, reflecting unique evolutionary pres-
sures acting on these specific biological processes opposed
to a universal pattern for all disease genes of early meta-
zoan origins. This suggests that some of the human
disease-related processes that evolved with multicellularity
in the earliest animal lineages are potentially under stron-
ger evolutionary constraints than those with unicellular
origins.
Discussion
Recent additions of non-bilaterian animal species with
whole-genome sequence data available motivated us to
analyze the evolutionary origins of human disease genes,
with a particular focus on these early periods of animal
evolution. One goal of this analysis was to determine the
potential utility of these species in modeling the genetics
underlying specific classes of human disease. With these
genomic data in hand, our results corroborate previous
findings that the majority of human disease genes are of
particularly ancient origins, having many more genes of
pre-animal origin than would be expected if disease
genes were a random subset of all human genes [3-5].
Through our analysis of additional early metazoan ge-
nomes, we find that there is also a significant over-
representation of early metazoan genes in the human
disease gene set, suggesting that the ancient skew of hu-
man disease gene origins extends into the early animal
lineages as well (see Additional files 2 and 3).
Figure 5 Distinct evolutionary pressures on disease classes of different origins in popular mammalian models. Comparison of the
distribution of human disease gene dN/dS ratios for the 29 deviating disease classes, separated according to their age-related signature as
defined in Figure 4: A) vertebrate-specific, B) early metazoan, and C) multi-stage metazoan classes, and compared across nine mammalian species
relative to the expected distribution of all human disease genes from OMIM. Points indicate median dN/dS with 95% confidence intervals. Only
statistically significant differences are displayed (Mann-Whitney U two-tailed test; p < 0.05, Bonferroni-corrected).
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of human disease genes has ancient origins. Rather, a
subset of disease classes (38% of those examined) show
significantly more recent origins than the superset of all
human disease genes, with many first appearing morefrequently within the Metazoa and Vertebrata. We iden-
tified three novel evolutionary signatures from this set,
all representing disease classes with over-representations
of metazoan-specific genes: the vertebrate-specific, early
metazoan, and multi-stage metazoan. Furthermore, we
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of a human disease class, are correlated with the ob-
served rates of evolutionary selective pressures (dN/dS
ratios). These two observations are made on different
evolutionary time scales, having age measured on a pre-
mammalian scale and evolutionary pressures measured
within mammals and primates. Specifically, we have
shown that human disease genes with vertebrate-specific
origins tend to be under weaker levels of purifying selec-
tion within mammals than human disease genes of pre-
vertebrate origins. This result contradicts findings that
younger disease genes are evolving particularly slowly
compared to non-disease genes; they appear to more
closely mimic the rates observed among all genes [4,46].
As a result, classes of human disease that contain many
vertebrate-specific genes are unlikely to be as highly
conserved in certain mammalian models as disease
classes of more ancient origins. Thus our results may
provide some insight regarding a handful of recent ex-
perimental findings addressing whether mice are poor
models of inflammatory diseases [35] and if certain im-
mune response genes can only be studied in primates or
humans [14], for example. Our evolutionary profiling
studies identified both inflammatory diseases and im-
munological diseases as having large proportions of
vertebrate-specific genes that are under weaker-than-
expected purifying selection, particularly in mice and
rats for inflammatory diseases and all species beyond old
world monkeys for immunological diseases.
Conversely, we also demonstrated that certain disease
classes with many genes of early metazoan origins are
under particularly strong rates of purifying selection
within mammalian lineages. This suggests that some
functional groups of human disease genes that arose at
the base of the Metazoa (and the biological processes
that they are responsible for) have distinct evolutionary
pressures. As a group, they appear to be more highly
conserved than both older and younger human disease
genes. While the evolutionary rates were not computed
beyond the eutherian mammals (due to issues of muta-
tional saturation in dS values), we speculate that this
trend continues to deeper branches of the metazoan tree
of life. To enable the investigation of subsets of disease
genes not considered in our analysis, we have provided
the complete phylostratigraphic distribution of our disease
gene set and corresponding dN/dS ratios in Additional
files 6 and 10, respectively.
In practice, if the distribution of dN/dS ratios for a
set of human disease genes with orthologs in a particu-
lar species is in fact correlated with the degree to which
the underlying disease process can be modeled, then
our results indicate that disease classes with over-
representations of vertebrate-specific genes may be
harder to mimic outside of our closest animal relatives.However, the opposite trend is observed for disease classes
with over-representations of genes found in the earliest
metazoan lineages, which appear to be under particularly
strict selective pressures; these disease genes may be pos-
sible to study in our more distantly related animal rela-
tives. In total, our phylostratigraphic analysis of individual
disease classifications has demonstrated that the majority
of disease classes (62% of those examined) do have ancient
origins, consistent with the distribution of all human dis-
ease genes. This collective evolutionary model tends to
have large proportions of genes that pre-date animals and
are well conserved within mammals. Thus, this majority
set of disease classes may also be promising candidates to
study in a more diverse set of animal species.
Our results imply that there may be utility in studying
disease genes that have primarily pre-vertebrate origins
in non-traditional animal models, especially in the case
of genes known to be lost or highly derived in popular
protostome models. From our analysis, we estimate that
as many as 10% of all human disease genes are absent or
highly derived in both C. elegans and D. melanogaster,
but have an ortholog in at least one more-distantly re-
lated species. These species generally have fast regener-
ation times, short life cycles, are inexpensive to culture,
and can teach us about the evolutionary context of con-
served disease genes and the most basic functions they
evolved to perform. Nonetheless, it is important to fac-
tor in the experimental tractability of these species, most
of which have not been developed into standard model
organisms. By endorsing their value to human disease
research through surveys such as this one, it is hoped
that the biomedical community will give serious consid-
eration to expanding the standard repertoire of model
organisms to include non-bilaterian animals. While non-
bilaterians such as sea anemones and ctenophores may
not seem tractable for human gene modeling, efforts are
currently underway to increase their utility as “emerging
model organisms” [18,20-22].
Conclusions
Taken together, the patterns we have identified highlight
the need for a wider evolutionary perspective to be con-
sidered when selecting appropriate model organisms for
studying a particular human disease or disorder. Our
results indicate that a one-to-one comparison of the hu-
man disease gene complement in a target model organ-
ism is insufficient to rationalize its use as a good model.
Rather, analysis of the evolutionary history correspond-
ing to the entire disease process being studied, as well as
establishing the system-wide context in which it plays a
part, can be decidedly more informative. We caution
against over-generalizing and approaching all human
disease genes as uniformly evolving collections of genes.
This further emphasizes the need to make model
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ation of evolutionary origins, experimental tractability,
and many other context-specific factors.
Future efforts to extend and refine our analyses could
theoretically produce methods that could direct an in-
vestigator to a set of model species that would be well-
suited to studying a particular human disease gene or
disease class. That said, there are many obstacles that
make this difficult to achieve at the present time. First,
the development of a standardized database or ontology
for annotating disease genes would be necessary to en-
able the comparison of disease phenotypes in greater
depth and breadth. Second, to more precisely decipher
the human disease gene content and tractability of emer-
ging animal models, additional sequence data from spe-
cies in the more sparsely represented sections of the
animal phylogenetic tree will be required. The majority
of existing data from these regions are EST traces that
suffer from low gene coverage [47,48]; efforts to expand
these genomic data with high-throughput transcriptome
sequencing may provide an alternative to whole-genome
sequencing for the purpose of mapping gene content
[49]. Third, as new genomic data continue to be gener-
ated for these distant species, our work could be ex-
tended with a method that more comprehensively
characterizes gene family relationships beyond orthol-
ogy, such as the methods used for the EnsemblCompara
GeneTrees [50] or other methods that define gene age
according to more dynamic properties [51]. To our
knowledge, these methods have yet to be applied with
the addition of newly sequenced genomes, especially
those from non-bilaterian animal lineages. The use of a
phylogenetic gene tree-based method would also enable
the estimation of dN values beyond mammals, which ap-
pear to be the driving force of the dN/dS ratio deviations
we have identified. Thus, despite dS value mutational
saturation issues, it may be possible to perform an ana-
lysis of selective evolutionary rates of human disease
genes over a larger evolutionary distance by considering
dN rate estimates alone. Finally, in order to more thor-
oughly investigate cases where certain animal models
would be inappropriate, there needs to be a platform by
which negative results can be reported in the literature.
With the addition of these hypothetical data and the im-
provement of methodologies for defining disease gene
family evolution on a genome-wide scale, it may be pos-
sible to develop comparative genomic tools to pinpoint
suitable animal models in a context-specific fashion.
Methods
Phylostratigraphic analysis with clusters of orthologous
genes
Clusters of genes with putative orthology in humans and
22 other species were generated using sequence similaritybased on BLAST and relative position in a predetermined
phylogenetic species tree (see Figure 1). We assigned bit
scores to hits between each pair of genes by summing
those for initial BLASTP high-scoring segments (HSPs)
found on the same pair of genes, in consistent order, and
overlapping less than 5% (with bit scores penalized pro-
portional to the amount of overlap, computed as the lar-
ger of overlap_fraction * HSP_score/HSP_length for the
two HSPs). We determined orthologous sets of genes at
each tree node in two steps. First, if a set or gene from
one child of the node was in a mutual best hit-relation
with a set or gene from the other child, they were com-
bined into a new set. Second, following this initial merge
step, we then considered all hits within the node’s subtree
and between the subtree and all outgroup genes in de-
scending order of bit score (in either source-target gene
direction). A better hit to an outgroup gene blocked any
further merging of a gene or set (until another tree node
was visited), while a hit between two sets or genes within
the subtree, neither previously blocked, resulted in these
being merged into a new set. This orthology computation
was based on that described and implemented for the gen-
ome sequence of Nematostella [30] with further refine-
ment of the blocking rules. Merging of species tree nodes
(and of the underlying sets of orthologous genes, where in
a mutual-best-hit or unblocked-hit relationship) continues
iteratively until the root node of the species tree is
reached. Additional information on the method’s imple-
mentation is provided in Additional file 12.
The resulting clusters represent families of orthologous
genes, and the distribution of genes within a cluster pro-
vides a picture of the presence/absence of a gene family
within the representative set of animals (and their closest
outgroups). The subset of clusters containing human
OMIM genes was used for further phylostratigraphic ana-
lysis. The phylostratification produced by this method is
more conservative than that of an unbiased, complete
BLAST database query to identify gene orthologs by simi-
larity threshold, such as the methods used in previous
phylostratigraphic studies [3], because the method adheres
to a discrete phylogenetic hierarchy, uses a scoring metric
that takes the length of sequence matches into account,
and is duplication-aware to the extent of distinguishing
orthologs and out-paralogs (in-paralogs would be inter-
preted as two distinct ancestral genes at any particular tree
node, but can become in-paralogous during subsequent
merges of parental tree nodes). Therefore, it aims to in-
crease specificity at the cost of sensitivity and provides
higher-confidence orthologous gene relationships than
those based simply on sequence similarity below a given
threshold. This method inherently employs a Dollo-type
parsimony model of gene evolution by assuming that gene
families evolved (or duplicated) once in a single common
ancestor. In order to qualitatively assess and contextualize
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results of a few gene families with known human disease
gene members to their previously reported phylogenetic
relationships. Our results, which are in agreement with
these previously reported phylogenetic relationships, show
that our clusters are able to detect a wide range of phylo-
genetically meaningful relationships (see Additional files
13 and 14).
Evaluation of evolutionary selection rates of disease gene
classes
We downloaded dN and dS evolutionary rates for all
human RefSeq genes from BioMart, which are pre-
computed for mammalian orthologs in the Ensembl-
Compara GeneTrees [50]; dS values become saturated
over larger evolutionary distances, restricting the species
we considered to a subset of eutherian mammals. We
assigned dN, dS, and dN/dS values to each human gene
ortholog from each of the nine mammalian species con-
sidered, selecting only the top ortholog based on orthol-
ogy confidence, sequence identity, and minimum dN/dS
ratio (in order). Of 19170 human genes considered, be-
tween 85.0% (rabbit) and 91.8% (chimpanzee) were
assigned dN and dS values. Of the 2727 disease genes
used in our phylostratigraphic analysis, between 91.6%
(rabbit) and 98.3% (mouse) were assigned, and within
disease class subsets, between 88.1% and 100% were
assigned, with a median value of 96.3%.
To determine whether disease genes from any particular
phylostratum had unique relative rates of selection, we
compared the dN/dS rate distributions of genes from each
phylostratum, restricted to the superset of all human dis-
ease genes with dN/dS ratios identified in every selected
mammalian species (2103 out of 2727 genes). Within each
mammalian species, dN/dS rate distributions were com-
pared between all pairs of phylostrata (Mann-Whitney U
two-tailed test; p < 0.05, Bonferroni-corrected). Only the
vertebrate-specific set shows any significant difference in
dN/dS distribution compared to the gene sets in other
phylostrata, and this difference is significant in every com-
parison except for, within chimpanzee, vertebrate-specific
genes versus genes in the Parahoxozoa and Bilateria phy-
lostrata, respectively (see Additional file 11).
Reproducibility of disease gene phylostratification using
reciprocal-best BLASTP searches
In order to assess the robustness of the phylostratifica-
tion produced by the clusters and the reproducibility of
the resulting evolutionary signatures of disease classes
presented in Figures 3 and 4, we performed a second
phylostratigraphic analysis using an alternative method.
In this case, all OMIM genes with an NCBI RefSeq pro-
tein counterpart (2874 total, including all 2727 from the
ortholog clusters) were queried against predicted proteinsets of each species independently with a reciprocal
BLASTP search. Thus, a given OMIM gene was identi-
fied as a reciprocal best BLASTP hit (RBH) to a non-
human gene within a given species if the OMIM gene
and candidate non-human gene were both best BLASTP
hits to the other, having E-values of less than 1 × 10−3 in
both cases. Thus, the RBH relationships between human
genes and the genes of a non-human species are one-to-
one and consider only OMIM genes, opposed to the re-
lationships defined by the ortholog clusters that are
many-to-many and include all human genes. The RBH
method is, therefore, even more specific than the ortho-
log clustering method, but also less sensitive, and should
not be expected to produce an identical phylostratification.
Nonetheless, we use this method to demonstrate that the
results of our analysis are reproducible and not dependent
upon the phylostratigraphic method. The results of the
RBH method are presented in Additional file 6.
We identified the overlap between the two methods
and found that 23,374 OMIM gene orthologs were also
identified as RBHs (excluding D. pulex, C. intestinalis,
and X. tropicalis due to problems arising from dif-
ferences in protein sequence identifiers; see Additional
files 4 and 5). This represents 70.2% of all OMIM ortho-
logs identified and 78.1% of all OMIM RBHs identified.
Overall, we found the two methods to be in relatively
strong agreement despite their stated differences, but
this highlights the fact that identifying homologs of hu-
man genes from diverse animal species is not an exact
science. In particular, it is confounded by the abundance
of gene families that arose via duplication(s) of a com-
mon ancestor and the interpretation as to which evolu-
tionary event (i.e., the emergence of the founder gene,
its duplication, or some other intermediate event) is the
most relevant. The most robust method would require
running phylogenetic trees on each OMIM gene, which
is not currently a tractable approach on a large, multiple
gene family scale because each tree is sensitive to the se-
lection of a suitable set of gene sequences (including
outgroups) and must be interpreted manually. Other
methods have considered treating emergence and most-
recent duplication events independently [6,50], but this
complicates the ability to study evolutionary distribu-
tions of large sets of genes and has not yet been applied
to newly sequenced genomes.
In addition to the reproducibility of individual ortho-
log or RBH assignments for OMIM genes, we also evalu-
ated the reproducibility of the phylostratification (i.e.,
the identification of the most distant ortholog) produced
by each method and the subsequent selection of signifi-
cantly deviating disease processes. These results are pre-
sented in Additional file 15. We found that 1696 of the
2727 OMIM genes that were considered in both methods
were placed in the same phylostratum, representing 62.2%
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an immediately adjacent bin (e.g., a gene identified as first
appearing in the Metazoa by one method, but in either the
Parahoxozoa or Filozoa in the other), the reproducibility
increases to 2173 (79.7%); thus, nearly half of the incon-
sistencies between binning methods are still close in
relative evolutionary distance. Another main source of dis-
crepancy lies in the fact that the ortholog clustering
method tends to produce a more ancient skew relative to
the RBH method, likely because RBHs are more stringent
in their similarity metric and more prone to false negatives
stemming from distantly diverging sequence. Thus, an
ortholog is identified in the Filozoa for 52% of the OMIM
genes, whereas only 46.2% have a RBH.
Despite the noted differences in the phylostratigraphic
methods, however, the selection of disease annotations
that significantly differ from the null (“All OMIM”)
model is highly reproducible across methods. Figure 3
identifies 29 significantly skewed disease distributions,
with 27 of these significantly skewed using the RBH
method as well. Therefore, the ortholog method identifies
only two annotations not reproduced by the RBH method
and, likewise, the RBH method identifies 11 uniquely (see
Additional file 6). These unique results generally have less
dramatic deviation from the null distribution than those
that are reproduced. When comparing the distributions
for reproduced annotations, the overall distributions are
expectedly not identical. However, the most statistically
significant over- and under-representations are well main-
tained between the two methods. We notice a number of
annotations that interchange between the multi-stage meta-
zoan group (Figure 4C) and either the vertebrate-specific
(Figure 4A) or early metazoan (Figure 4B) group between
phylostratigraphic methods, but no cases exist where a dis-
ease annotation was placed in the vertebrate-specific group
by one method and the early metazoan group by the other.
Therefore, some of the marginal over-representations iden-
tified in one method may not be identified as significant in
the other, but we found no cases of major disagreement.
Finally, we compared the distributions for each annotation
(both non-deviating and significantly deviating) across
phylostratigraphic methods and found that while the two
distributions for each matching annotation are not identi-
cal, they are more similar than expected based on all pairs
of across-method distribution comparisons (calculated
using χ2 two-sample test statistics adjusted for equal de-
grees of freedom, one-tailed t-test of means where N = 76
and 5927 defined comparisons, p = 0.0086).
Estimation of sampling errors from choice of taxa
The evolutionary distributions we have compared are
dependent upon the sample of species used and their
grouping into phylostrata. Our analysis is limited by the
few species with whole-genome sequence available indistant animal lineages. While the goal of our analysis
was not to identify founder genes, we nonetheless esti-
mated what percentage of genes have origins much dee-
per than the Filozoa, and more specifically, how many of
those were considered in our analysis to be Metazoa-
specific. For example, if a disease gene has more ancient
origin than the species we have studied but was lost in
both M. brevicollis and C. owcarzaki, then we cannot
conclude whether a gene binned in the Metazoa in fact
has Metazoa-specific origins, or if it was simply lost in
the Filozoan species we included. To estimate the occur-
rence of these events, we performed an independent
RBH comparison of the human disease gene (OMIM)
set versus the genome of the yeast S. cerevisiae, yielding
a set of 676 genes out of 2874 (23.5%). This was used as
a representative set of genes that could be considered to
have pre-metazoan origins with relatively high confidence.
We then compared the phylostratification of this gene set
by each phylostratigraphic method to see how often these
yeast genes were placed in the most basal phylostratum
(Filozoa), indicating likely pre-metazoan origins.
For the ortholog clustering method, 655 of the 676
yeast homologs were included in our clusters. 572 of
these were binned in the Filozoa, suggesting the other
83 are found only in our metazoan genomes, indicating
potential loss in the filozoans we studied. This repre-
sents about 3% of the 2727 clustered genes: 51 were in-
stead binned in the Metazoa, eight in the Parahoxozoa,
five in the Bilateria, four in the Deuterostomia, and 15
in the Vertebrata. For the RBH method of phylostratifi-
cation, 47 of the 676 yeast homologs were not binned in
the Filozoa, representing about 1.6% of the 2874 genes
with RBHs. 25 of these were instead binned in the
Metazoa, 12 in the Parahoxozoa, four in the Bilateria,
one in the Deuterostomia, and five in the Vertebrata.
These data suggest that despite not looking beyond the
Filozoa, very few genes with likely pre-metazoan origins
were considered Metazoa-specific in our analyses.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article and its additional files.
Additional files
Additional file 1: Species included in the phylostratigraphic
analysis and the accompanying predicted proteome sources.
Additional file 2: Number of genes binned in each phylostratum
for gene sets including all human genes, human disease genes
(OMIM), or human disease genes that did or did not receive at least
one annotation from IPA.
Additional file 3: Comparison of the evolutionary distribution of
the human disease gene subset (orange) versus all human genes
(y=0; data not shown). χ2 two-sample test, p = 2.2 × 10−16. Numbers of
genes binned into individual phylostrata were further compared, showing
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representations in the Deuterostomia and Vertebrata phylostrata
(hypergeometric test; ***p < 1.0 × 10−20, **p < 0.001, *p < 0.01).
Additional file 4: Number of OMIM genes identified in each species
by each phylostratigraphic method. [An asterisk (*) denotes taxa
deemed unreliable due to mismapped sequence identifiers].
Additional file 5: Number of human disease gene (OMIM) orthologs
and RBHs identified in each species studied, with overlap between
the two indicated.
Additional file 6: Results of phylostratigraphic analyses and disease
gene annotations.
Additional file 7: Vertebrate-specific level-2 disease annotations.
Additional file 8: Early metazoan level-2 disease annotations.
Additional file 9: Multi-stage metazoan level-2 disease annotations.
Additional file 10: Disease gene dN, dS, and dN/dS values in each
mammalian species considered.
Additional file 11: Median dN/dS ratios for all disease genes in
each phylostratum for each mammalian species considered.
Additional file 12: Pseudocode describing the ortholog clustering
algorithm used for phylostratification of human disease genes.
Additional file 13: Clusters of human disease genes that are known
members of multi-gene families. (A) Apolipoproteins, (B) Caspase
enzymes, and (C) components of the TGF-β signaling pathway.
Additional file 14: Qualitative assessment of ortholog clusters [52-63].
Additional file 15: Number of genes binned in each phylostratum
by ortholog clusters and RBHs.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EKM, CES, and ADB conceived and designed the research. EKM, CES, PH,
NHP, ADN, RTM, and ADB performed the research. PH and NHP contributed
and performed the ortholog clustering method. EKM, CES, ADN, RTM, and
ADB analyzed the data. EKM, CES, and ADB wrote the paper. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by the Intramural Research Program of the
National Human Genome Research Program, National Institutes of Health.
This work was also supported through NSF grant EF-0850294 to NHP. We
would like to thank Tyra Wolfsberg for her critical reading of this manuscript,
support, and advice throughout this project. We would like to thank Joseph
Ryan for his thoughtful comments and insights regarding this study. We
would like to thank Steve Bond and Shawn Burgess for their critical reading
of the manuscript. We also thank Niraj Trivedi for his assistance with using
the Ingenuity Pathway Analysis® software suite.
Author details
1Computational and Statistical Genomics Branch, Division of Intramural
Research, National Human Genome Research, National Institutes of Health,
Bethesda, MD 20892, USA. 2Bioinformatics Program, Boston University,
Boston, MA 02215, USA. 3Department of Ecology and Evolutionary Biology,
Rice University, Houston, Texas 77005, USA. 4Biomedical Informatics Core,
College of Medicine, Texas A&M Health Science Center, Houston, Texas
77030, USA.
Received: 30 May 2014 Accepted: 25 September 2014
References
1. Feldman I, Rzhetsky A, Vitkup D: Network properties of genes harboring
inherited disease mutations. Proc Natl Acad Sci U S A 2008, 105:4323–4328.
2. Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabási A-L: The human
disease network. Proc Natl Acad Sci U S A 2007, 104:8685–8690.3. Domazet-Loso T, Tautz D: An ancient evolutionary origin of genes associated
with human genetic diseases. Mol Biol Evol 2008, 25:2699–2707.
4. Cai JJ, Borenstein E, Chen R, Petrov DA: Similarly strong purifying selection
acts on human disease genes of all evolutionary ages. Genome Biol Evol
2009, 1:131–144.
5. Lopez-Bigas N: Genome-wide identification of genes likely to be involved
in human genetic disease. Nucleic Acids Res 2004, 32:3108–3114.
6. Dickerson JE, Robertson DL: On the origins of Mendelian disease genes in
man: the impact of gene duplication. Mol Biol Evol 2012, 29:61–69.
7. Peterson KJ, Cotton JA, Gehling JG, Pisani D: The Ediacaran emergence of
bilaterians: congruence between the genetic and the geological fossil
records. Philos Trans Royal Soc B: Biol Sci 2008, 363:1435–1443.
8. Rubin GM, Yandell MD, Wortman JR, Gabor GL, Nelson CR, Hariharan IK,
Fortini ME, Li PW, Apweiler R, Fleischmann W: Comparative genomics of
the eukaryotes. Science 2000, 287:2204–2215.
9. Sullivan JC, Finnerty JR: A surprising abundance of human disease genes
in a simple “basal” animal, the starlet sea anemone (Nematostella
vectensis). Genome 2007, 50:689–692.
10. Berghmans S, Jette C, Langenau D, Hsu K, Stewart R, Look T, Kanki JP:
Making waves in cancer research: new models in the zebrafish.
BioTechniques 2005, 39:227–237.
11. Ratajczak CK, Muglia LJ: Insights into parturition biology from genetically
altered mice. Pediatr Res 2008, 64:581–589.
12. Norton W, Bally-Cuif L: Adult zebrafish as a model organism for behavioural
genetics. BMC Neurosci 2010, 11:90.
13. Murphy DL, Lesch K-P: Targeting the murine serotonin transporter:
insights into human neurobiology. Nat Rev Neurosci 2008, 9:85–96.
14. Chen CY, Huang D, Wang RC, Shen L, Zeng G, Yao S, Shen Y, Halliday L,
Fortman J, McAllister M: A critical role for CD8 T cells in a nonhuman
primate model of tuberculosis. PLoS Pathog 2009, 5:e1000392.
15. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME,
Kauppinen S, Ørum H: Therapeutic silencing of microRNA-122 in primates
with chronic hepatitis C virus infection. Science 2010, 327:198–201.
16. Kaletta T, Hengartner MO: Finding function in novel targets: C. elegans as
a model organism. Nat Rev Drug Discov 2006, 5:387–398.
17. Pandey UB, Nichols CD: Human disease models in Drosophila
melanogaster and the role of the fly in therapeutic drug discovery.
Pharmacol Rev 2011, 63:411–436.
18. Reitzel AM, Ryan JF, Tarrant AM: Establishing a model organism: a report
from the first annual Nematostella meeting. BioEssays 2012, 34:158–161.
19. Martindale MQ, Lee PN: The development of form: Causes and
consequences of developmental reprogramming associated with rapid
body plan evolution in the bilaterian radiation. Biol Theory 2013, 8:253–264.
20. Pang K, Martindale MQ: Comb jellies (Ctenophora): a model for basal
metazoan evolution and development. CSH Protoc 2008, pdb.emo106.
21. Pang K, Martindale MQ: Ctenophores. Curr Biol 2008, 18:R1119–R1120.
22. Plickert G, Frank U, Müller WA: Hydractinia, a pioneering model for stem
cell biology and reprogramming somatic cells to pluripotency. Int J Dev
Biol 2012, 56:519–534.
23. Institute of Medicine (US) and National Research Council (US) Committee
on the Use of Chimpanzees in Biomedical and Behavioral Research,
Altevogt BM, Pankevich DE, Shelton-Davenport MK, Kahn JP: Chimpanzees in
Biomedical and Behavioral Research: Assessing the Necessity. Washington (DC):
National Academies Press (US); 2011.
24. Rongvaux A, Willinger T, Takizawa H, Rathinam C, Auerbach W, Murphy AJ,
Valenzuela DM, Yancopoulos GD, Eynon EE, Stevens S: Human
thrombopoietin knockin mice efficiently support human hematopoiesis
in vivo. Proc Natl Acad Sci U S A 2011, 108:2378–2383.
25. Jucker M: The benefits and limitations of animal models for translational
research in neurodegenerative diseases. Nat Med 2010, 16:1210–1214.
26. de Jong M, Maina T: Of mice and humans: are they the same?–
Implications in cancer translational research. J Nucl Med 2010, 51:501–504.
27. Ryan JF, Pang K, Schnitzler CE, Nguyen A-D, Moreland RT, Simmons DK, Koch
BJ, Francis WR, Havlak P, Comparative Sequencing Program NISC, Smith SA,
Putnam NH, Haddock SHD, Dunn CW, Wolfsberg TG, Mullikin JC, Martindale
MQ, Baxevanis AD: The genome of the ctenophore Mnemiopsis leidyi and
its implications for cell type evolution. Science 2013, 342:1242592.
28. Srivastava M, Simakov O, Chapman J, Fahey B, Gauthier MEA, Mitros T,
Richards GS, Conaco C, Dacre M, Hellsten U, Larroux C, Putnam NH, Stanke
M, Adamska M, Darling A, Degnan SM, Oakley TH, Plachetzki DC, Zhai Y,
Adamski M, Calcino A, Cummins SF, Goodstein DM, Harris C, Jackson DJ,
Maxwell et al. BMC Evolutionary Biology 2014, 14:212 Page 17 of 17
http://www.biomedcentral.com/1471-2148/14/212Leys SP, Shu S, Ben J, Woodcroft Vervoort M, Kosik KS, et al: The
Amphimedon queenslandica genome and the evolution of animal
complexity. Nature 2010, 466:720–726.
29. Srivastava M, Begovic E, Chapman J, Putnam NH, Hellsten U, Kawashima T,
Kuo A, Mitros T, Salamov A, Carpenter ML, Signorovitch AY, Moreno MA,
Kamm K, Grimwood J, Schmutz J, Shapiro H, Grigoriev IV, Buss LW,
Schierwater B, Dellaporta SL, Rokhsar DS: The Trichoplax genome and the
nature of placozoans. Nature 2008, 454:955–960.
30. Putnam NH, Srivastava M, Hellsten U, Dirks B, Chapman J, Salamov A, Terry
A, Shapiro H, Lindquist E, Kapitonov VV, Jurka J, Genikhovich G, Grigoriev IV,
Lucas SM, Steele RE, Finnerty JR, Technau U, Martindale MQ, Rokhsar DS:
Sea anemone genome reveals ancestral eumetazoan gene repertoire
and genomic organization. Science 2007, 317:86–94.
31. Ruiz-Trillo I, Burger G, Holland PWH, King N, Lang BF, Roger AJ, Gray MW:
The origins of multicellularity: a multi-taxon genome initiative. Trends
Genet 2007, 23:113–118.
32. Gabaldón T, Koonin EV: Functional and evolutionary implications of gene
orthology. Nat Rev Genet 2013, 14:360–366.
33. Domazet-Loso T, Tautz D: Phylostratigraphic tracking of cancer genes suggests
a link to the emergence of multicellularity in metazoa. BMC Biol 2010, 8:66.
34. Podder S, Ghosh TC: Exploring the differences in evolutionary rates
between monogenic and polygenic disease genes in human. Mol Biol
Evol 2010, 27:934–941.
35. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR,
McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S,
Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB,
Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein
BH, Miller-Graziano C, Calvano SE, Mason PH, et al: Genomic responses in
mouse models poorly mimic human inflammatory diseases. Proc Natl
Acad Sci U S A 2013, 110:3507–3512.
36. Martin B, Ji S, Maudsley S, Mattson MP: “Control” laboratory rodents are
metabolically morbid: why it matters. Proc Natl Acad Sci U S A 2010,
107:6127–6133.
37. Schäfer S, Kolkhof P: Failure is an option: learning from unsuccessful
proof-of-concept trials. Drug Discov Today 2008, 13:913–916.
38. Böhm SV, Constantinou P, Tan S, Jin H, Roberts RG: Profound human/
mouse differences in alpha-dystrobrevin isoforms: a novel syntrophin-
binding site and promoter missing in mouse and rat. BMC Biol 2009, 7:85.
39. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V,
Macleod MR: Can animal models of disease reliably inform human
studies? PLoS Med 2010, 7:e1000245.
40. Tsilidis KK, Panagiotou OA, Sena ES, Eleni A, Evangelou E, Howells DW, Salman
RA-S, Macleod MR, Ioannidis JPA: Evaluation of excess significance bias in
animal studies of neurological diseases. PLoS Biol 2013, 11:e1001609.
41. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA: Online
Mendelian Inheritance in Man (OMIM), a knowledgebase of
human genes and genetic disorders. Nucleic Acids Res 2005,
33(Database issue):D514–D517.
42. Domazet-Loso T, Brajković J, Tautz D: A phylostratigraphy approach to
uncover the genomic history of major adaptations in metazoan lineages.
Trends Genet 2007, 23:533–539.
43. Kortschak RD, Samuel G, Saint R, Miller DJ: EST analysis of the cnidarian
Acropora millepora reveals extensive gene loss and rapid sequence
divergence in the model invertebrates. Curr Biol 2003, 13:2190–2195.
44. Raible F, Arendt D: Metazoan evolution: some animals are more equal
than others. Curr Biol 2004, 14:R106–R108.
45. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE,
Humphray S, McLaren K, Matthews L, McLaren S, Sealy I, Caccamo M,
Churcher C, Scott C, Barrett JC, Koch R, Rauch G-J, White S, Chow W, Kilian
B, Quintais LT, Guerra-Assunção JA, Zhou Y, Gu Y, Yen J, Vogel J-H, Eyre T,
Redmond S, Banerjee R, et al: The zebrafish reference genome sequence
and its relationship to the human genome. Nature 2013, 496:498–503.
46. Wolf YI, Novichkov PS, Karev GP, Koonin EV, Lipman DJ: The universal
distribution of evolutionary rates of genes and distinct characteristics of
eukaryotic genes of different apparent ages. Proc Natl Acad Sci U S A
2009, 106:7273–7280.
47. Dunn CW, Hejnol A, Matus DQ, Pang K, Browne WE, Smith SA, Seaver E,
Rouse GW, Obst M, Edgecombe GD, Sørensen MV, Haddock SHD, Schmidt-
Rhaesa A, Okusu A, Kristensen RM, Wheeler WC, Martindale MQ, Giribet G:
Broad phylogenomic sampling improves resolution of the animal tree of
life. Nature 2008, 452:745–749.48. Hejnol A, Obst M, Stamatakis A, Ott M, Rouse GW, Edgecombe GD, Martinez P,
Baguñà J, Bailly X, Jondelius U, Wiens M, Müller WEG, Seaver E, Wheeler WC,
Martindale MQ, Giribet G, Dunn CW: Assessing the root of bilaterian animals
with scalable phylogenomic methods. Proc Biol Sci 2009, 276:4261–4270.
49. Riesgo A, Andrade SCS, Sharma PP, Novo M, Pérez-Porro AR, Vahtera V,
González VL, Kawauchi GY, Giribet G: Comparative description of ten
transcriptomes of newly sequenced invertebrates and efficiency
estimation of genomic sampling in non-model taxa. Front Zool 2012, 9:33.
50. Vilella AJ, Severin J, Ureta-Vidal A, Heng L, Durbin R, Birney E: EnsemblCompara
GeneTrees: Complete, duplication-aware phylogenetic trees in vertebrates.
Genome Res 2009, 19:327–335.
51. Capra JA, Stolzer M, Durand D, Pollard KS: How old is my gene? Trends
Genet 2013, 29:659–668.
52. Hayward A, Takahashi T, Bendena WG, Tobe SS, Hui JHL: Comparative
genomic and phylogenetic analysis of vitellogenin and other large lipid
transfer proteins in metazoans. FEBS Lett 2010, 584:1273–1278.
53. Babin PJ, Gibbons GF: The evolution of plasma cholesterol: direct utility
or a “spandrel” of hepatic lipid metabolism? Prog Lipid Res 2009, 48:73–91.
54. Babin PJ, Thisse C, Durliat M, Andre M, Akimenko MA, Thisse B: Both
apolipoprotein E and A-I genes are present in a nonmammalian vertebrate
and are highly expressed during embryonic development. Proc Natl Acad
Sci U S A 1997, 94:8622–8627.
55. Li W-H, Tanimura M, Luo C-C, Datta S, Chan L: The apolipoprotein multigene
family: biosynthesis, structure, structure-function relationships, and
evolution. J Lipid Res 1988, 29:245–271.
56. Boguski MS, Birkenmeier EH, Elshourbagy NA, Taylor JM, Gordon JI: Evolution of
the apolipoproteins. Structure of the rat apo-A-IV gene and its relationship
to the human genes for apo-A-I, C-III, and E. J Biol Chem 1986, 261:6398–6407.
57. Dunn SR, Phillips WS, Spatafora JW, Green DR, Weis VM: Highly conserved
caspase and Bcl-2 homologues from the sea anemone Aiptasia pallida:
lower metazoans as models for the study of apoptosis evolution. J Mol
Evol 2006, 63:95–107.
58. Lamkanfi M: Alice in caspase land. A phylogenetic analysis of caspases
from worm to man. Cell Death Differ 2002, 9:358–361.
59. Taylor RC, Cullen SP, Martin SJ: Apoptosis: controlled demolition at the
cellular level. Nat Rev Mol Cell Biol 2008, 9:231–241.
60. Lamkanfi M, Kalai M, Vandenabeele P: Caspase-12: an overview. Cell Death
Differ 2003, 11:365–368.
61. Richards GS, Degnan BM: The dawn of developmental signaling in the
metazoa. Cold Spring Harb Symp Quant Biol 2009, 74:81–90.
62. Pang K, Ryan JF, Baxevanis AD, Martindale MQ: Evolution of the TGF-β
Signaling Pathway and Its Potential Role in the Ctenophore, Mnemiopsis
leidyi. PLoS One 2011, 6:e24152.
63. Detournay O, Schnitzler CE, Poole A, Weis VM: Regulation of cnidarian-
dinoflagellate mutualisms: Evidence that activation of a host TGFβ
innate immune pathway promotes tolerance of the symbiont. Dev Comp
Immunol 2012, 38:525–537.
doi:10.1186/s12862-014-0212-1
Cite this article as: Maxwell et al.: Evolutionary profiling reveals the
heterogeneous origins of classes of human disease genes: implications
for modeling disease genetics in animals. BMC Evolutionary Biology
2014 14:212.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
